Beijing Kawin Technology Share-holding Co Ltd (688687) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.014x

Based on the latest financial reports, Beijing Kawin Technology Share-holding Co Ltd (688687) has a cash flow conversion efficiency ratio of 0.014x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥26.41 Million ≈ $3.86 Million USD) by net assets (CN¥1.83 Billion ≈ $267.07 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Beijing Kawin Technology Share-holding Co Ltd - Cash Flow Conversion Efficiency Trend (2009–2025)

This chart illustrates how Beijing Kawin Technology Share-holding Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. See Beijing Kawin Technology Share-holding C (688687) net assets for net asset value and shareholders' equity analysis.

Beijing Kawin Technology Share-holding Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Beijing Kawin Technology Share-holding Co Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Asia Aviation Public Company Limited
BK:AAV
0.385x
CJ Corp 4P Pref 
KO:00104K
0.102x
Shenzhen Huakong Seg Co Ltd
SHE:000068
0.070x
Panoro Energy ASA
OL:PEN
0.139x
Monopar Therapeutics Inc
NASDAQ:MNPR
0.000x
Manitowoc Company Inc
NYSE:MTW
0.040x
Binh Minh Plastics JSC
VN:BMP
0.139x
YTL Hospitality REIT
KLSE:5109
0.012x

Annual Cash Flow Conversion Efficiency for Beijing Kawin Technology Share-holding Co Ltd (2009–2025)

The table below shows the annual cash flow conversion efficiency of Beijing Kawin Technology Share-holding Co Ltd from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see 688687 stock market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CN¥1.74 Billion
≈ $254.60 Million
CN¥110.29 Million
≈ $16.14 Million
0.063x +14.30%
2024-12-31 CN¥1.88 Billion
≈ $275.15 Million
CN¥104.29 Million
≈ $15.26 Million
0.055x -21.79%
2023-12-31 CN¥1.79 Billion
≈ $261.23 Million
CN¥126.60 Million
≈ $18.53 Million
0.071x -11.02%
2022-12-31 CN¥1.68 Billion
≈ $246.10 Million
CN¥134.05 Million
≈ $19.62 Million
0.080x +14.04%
2021-12-31 CN¥1.69 Billion
≈ $246.93 Million
CN¥117.94 Million
≈ $17.26 Million
0.070x -54.60%
2020-12-31 CN¥853.63 Million
≈ $124.91 Million
CN¥131.42 Million
≈ $19.23 Million
0.154x +15.43%
2019-12-31 CN¥771.85 Million
≈ $112.95 Million
CN¥102.94 Million
≈ $15.06 Million
0.133x +44.82%
2018-12-31 CN¥654.87 Million
≈ $95.83 Million
CN¥60.31 Million
≈ $8.83 Million
0.092x +297.24%
2017-12-31 CN¥612.36 Million
≈ $89.61 Million
CN¥14.20 Million
≈ $2.08 Million
0.023x +55.63%
2015-12-31 CN¥545.83 Million
≈ $79.87 Million
CN¥8.13 Million
≈ $1.19 Million
0.015x -92.81%
2014-12-31 CN¥239.73 Million
≈ $35.08 Million
CN¥49.67 Million
≈ $7.27 Million
0.207x +172.70%
2013-12-31 CN¥220.74 Million
≈ $32.30 Million
CN¥16.77 Million
≈ $2.45 Million
0.076x -56.11%
2012-12-31 CN¥163.93 Million
≈ $23.99 Million
CN¥28.38 Million
≈ $4.15 Million
0.173x -34.24%
2011-12-31 CN¥122.53 Million
≈ $17.93 Million
CN¥32.26 Million
≈ $4.72 Million
0.263x -2.90%
2010-12-31 CN¥92.84 Million
≈ $13.59 Million
CN¥25.17 Million
≈ $3.68 Million
0.271x -39.47%
2009-12-31 CN¥38.91 Million
≈ $5.69 Million
CN¥17.43 Million
≈ $2.55 Million
0.448x --

About Beijing Kawin Technology Share-holding Co Ltd

SHG:688687 China Biotechnology
Market Cap
$432.50 Million
CN¥2.96 Billion CNY
Market Cap Rank
#13269 Global
#4051 in China
Share Price
CN¥17.29
Change (1 day)
-2.48%
52-Week Range
CN¥17.29 - CN¥38.59
All Time High
CN¥40.56
About

Beijing Kawin Technology Share-Holding Co., Ltd., a biopharmaceutical company, provides treatment solutions for viral and immune diseases in China and internationally. The company offers recombinant human interferon alfa-2b injection; interferon alfa-2b vaginal effervescent tablets; coblopasvir hydrocholoride capsules; sofosbuvir tablets; peginterferon alfacon-2 injection; and compound glycyrrhiz… Read more